Sarepta (SRPT) COO earns 1,875 PSUs tied to performance milestones

Rhea-AI Filing Summary

Sarepta Therapeutics, Inc. Chief Operating Officer Ian Michael Estepan reported an equity compensation transaction involving performance stock units. He acquired 1,875 performance stock units on February 25, 2026 as a grant/award, bringing his directly held performance stock units to 8,125.

According to the disclosure, these 1,875 shares represent units earned under a performance stock unit award originally granted on March 1, 2024, based on the compensation committee’s determination of the company’s achievement of specified milestones. The earned units are scheduled to vest on March 1, 2026, if he continues to provide service to the company through that date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Estepan Ian Michael

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Performance Stock Units	1,875	$0.00	--

Holdings After Transaction: Performance Stock Units — 8,125 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Estepan Ian Michael

(Last) (First) (Middle)

215 FIRST STREET

SUITE 415

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Sarepta Therapeutics, Inc. [ SRPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/25/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Stock Units	(1)	02/25/2026		A		1,875		(1)	(1)	Common Stock	1,875	(1)	8,125	D

Explanation of Responses:

1. Represents the number of shares earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 1, 2026, subject to the Reporting Person continuing to provide service to the Company through such vesting date.

	/s/ Cristin L. Rothfuss, as Attorney-in-Fact for Ian Michael Estepan	02/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Sarepta (SRPT) COO Ian Michael Estepan report in this Form 4?

Ian Michael Estepan reported acquiring 1,875 performance stock units as an equity award. These units increase his directly held performance stock units to 8,125, reflecting compensation tied to Sarepta’s achievement of specified performance milestones.

When were the performance stock units related to this Sarepta (SRPT) Form 4 originally granted?

The performance stock units were originally granted on March 1, 2024. The 1,875 units now reported represent the portion earned under that award, based on the compensation committee’s determination of Sarepta’s achievement of the prescribed performance milestones.

What performance criteria determined the 1,875 earned PSUs for Sarepta (SRPT) COO?

The 1,875 earned performance stock units were based on the compensation committee’s assessment of Sarepta’s achievement of defined milestones. These milestones were prescribed under the terms of the March 1, 2024 PSU award and govern how many units the executive ultimately earns.

When will the 1,875 earned performance stock units for Sarepta (SRPT) COO vest?

The 1,875 earned performance stock units are scheduled to vest on March 1, 2026. Vesting is conditioned on Ian Michael Estepan continuing to provide service to Sarepta Therapeutics through that vesting date under the award’s terms.

How many performance stock units does Sarepta (SRPT) COO hold after this transaction?

Following the reported transaction, Ian Michael Estepan directly holds 8,125 performance stock units. This total includes the 1,875 units earned based on Sarepta’s achievement of performance milestones under the March 1, 2024 PSU grant.

Is the Sarepta (SRPT) Form 4 transaction a cash purchase or an equity award?

The Form 4 transaction is an equity award acquisition, not a cash market purchase. The COO received 1,875 performance stock units as a grant based on milestone achievement, with no price per unit reported above zero.